VIREAD 245mg price in UAE

Overview

Welcome to Dwaey, specifically on VIREAD 245mg Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Tenofovir disoproxil fumarate.
VIREAD 245mg is available in the market in concentration 300mg/Tablet and in the form of Tablets/Film-coated.

GILEAD SCIENCES LIMITED is the producer of VIREAD 245mg and it is imported from IRELAND, The most popular alternatives of VIREAD 245mg are listed downward .

Mode Of Action

Tenofovir disoproxil fumarate, a diester prodrug of tenofovir, is a nucleotide reverse transcriptase inhibitor. After oral absorption, tenofovir disoproxil fumarate is rapidly converted to tenofovir and then undergo subsequent phosphorylation by cellular enzymes to the active tenofovir diphosphate, which inhibits the activity of HIV-1 reverse transcriptase.

Indication

HIV-1 infection
Chronic hepatitis B

Precaution

Patient w/ hepatomegaly or other risk factors for liver disease. Renal impairment. Pregnancy. Patient Counselling This drug may cause dizziness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor renal function and serum phosphate concentrations before start of therapy, 4 wkly during the 1st wk, and then 3 mthly; hepatic function for several mth following discontinuation. Determine HIV status in all hepatitis B virus (HBV) infected patients prior to treatment. Lactation: HIV+ women are advised not to breastfeed

Side Effects

>10% Asthenia (11%)
Diarrhea (16%)
Nausea (11%)
Pain (12%) 1-10% Anorexia
Depression
Myalgia
Peripheral neuropathy
Dyspepsia
Rash
Headache
Vomiting
Flatulence
Abdominal pain
Neutropenia
Increased transaminases

Contra indication

Tenofovir is contraindicated in patients with previously demonstrated hypersensitivity to Tenofovir or any component of the product.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Interaction

Decreased atazanavir concentration with tenofovir unless also co-administered with ritonavir. Increased serum concentration of tenofovir or co-administered drug if taken with drugs that are eliminated by active tubular secretion. Potentially Fatal: Increased risk of renal impairment with recent or concurrent use of nephrotoxic agents (e.g. aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir or interleukin-2); monitor renal function wkly if unavoidable. Increased didanosine levels and thereby increasing risk of pancreatitis and peripheral neuropathy, with a high treatment failure rate with concurrent use; avoid concurrent use.